Viatris receives U.S. FDA approval for Ryzumvi to treat presbyopia

VTRS•2026-10-16

Viatris received U.S. FDA approval for Ryzumvi to treat presbyopia and is exploring a U.S. commercialization partner for the drug.

1. FDA approval

Viatris received U.S. FDA approval for Ryzumvi for the treatment of presbyopia. The company is exploring a U.S. commercialization partner for the drug.

Viatris receives U.S. FDA approval for Ryzumvi to treat presbyopia

1. FDA approval

Related News

MiniMed grants director Amy Bricker 11,877 restricted stock units

GoPro to restate financial reports after debt accounting errors

CRISPR Therapeutics director Simeon George reports sale of shares worth $720,373.362

Align Alternative Access Fund offers to purchase up to 5% of net assets at NAV

Celanese announces global price increases for liquid crystal polymer products